EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT ® (Siltuximab for Injection) in China
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Siltuximab is a monoclonal antibody approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). iMCD is a rare, life-threatening and debilitating condition of the lymph nodes and related tissues. Siltuximab is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005360/en/
“The BLA acceptance of siltuximab for review, an important treatment approved in more than 40 countries worldwide for iMCD, is good news for Chinese patients with this rare condition,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. “We’re glad to see continued progress in our collaboration with EUSA, which was built upon our shared commitment to bringing impactful therapies to patients in China and around the world.”
Lee Morley, Chief Executive Officer of EUSA Pharma, said, “The BLA acceptance of siltuximab for review in China represents another exciting step in delivering therapies to patients in need worldwide. We will continue in our close collaboration with BeiGene and the NMPA to potentially bring siltuximab to iMCD patients in China.”
Siltuximab is a monoclonal antibody that directly neutralises IL-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions. Siltuximab (SYLVANT®) is currently approved by the US Food and Drug Administration (FDA) and the European Commission (EC), as well as regulatory authorities in several other jurisdictions worldwide, for the treatment of adult patients with Multicentric Castleman Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Indications and Usage – See EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information for additional information.
About EUSA Pharma
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company is headquartered in Hemel Hempstead, England (UK), and has extensive commercial operations in the United States and Europe, alongside a direct presence in selected other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and it is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information, please visit www.eusapharma.com.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential approval, launch and opportunity of SYLVANT® in China, future development and potential commercialization activities of the products under the agreement with EUSA, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
GL-SIL-2100006. January 2021
+44 7909 703627
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Red Fox ID and Cepton Enable Barrier-Free, High-Speed Tolling Worldwide With High Performance Lidar Based Solutions2.3.2021 14:00:00 CET | Press release
A state-of-the art electronic tolling system that utilizes high-performance lidar sensors from Cepton and a cutting-edge vehicle identification solution from Red Fox ID is expected to be deployed on a major highway turnpike crossing multiple states in the United States, thereby promising fast, highly accurate, barrier-free, real-time tolling to enable smooth traffic flows. This marks the maturing of the deep partnership between Cepton and Red Fox ID in bringing innovative, automated tolling solutions to major customers across North America, EMEA and Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005524/en/ Cepton’s MMT®-powered Sora-P lidars feature an industry-leading 380 Hz frame rate to deliver 1140 line scans per second, providing high-fidelity profiling of vehicles passing at highway speeds. © 2021 Cepton Technologies. Based on an extended collaboration with leading lidar solution provider Cepton, Red Fox ID
ALPINION Launches X-CUBE 90, A High-Performance Ultrasound Diagnostic System2.3.2021 14:00:00 CET | Press release
ALPINION MEDICAL SYSTEMS Co., Ltd (ALPINION), a medical ultrasound professional, announced that it will launch X-CUBE 90 in March. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005348/en/ ALPINION MEDICAL SYSTEMS launches X-CUBE 90, a high-performance ultrasound diagnostic system. X-CUBE 90 provides high-resolution diagnostic images with X+ Architecture. X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. X-CUBE 90 increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products. (Photo: Business Wire) X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. Compared to the existing models, X-CUBE 90 provides a more detailed image and comfortable user interface and thus a diagnostic environment of greater efficiency. X-CUBE 90 appl
Sintavia Acquires Three Additional GE Additive Arcam A2X Electron Beam Printers2.3.2021 13:59:00 CET | Press release
Sintavia, LLC, a designer and 3D printer of a new generation of flight and launch components, announced today that it had acquired three GE Additive Arcam A2X electron beam printers. The new electron beam printers will join the company’s four other electron beam printers, including three GE Additive Arcam Q20plus machines and one other A2X. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005184/en/ (Photo: Business Wire) “We are big believers in the electron beam process for high precision structural components manufactured in titanium,” said Brian Neff, Sintavia’s Chief Executive Officer. “It has been a great pleasure to work with GE Additive to develop successful manufacturing strategies for critical aerostructure components. We are excited to expand our production platform using the electron beam process in the months and years to come.” “It’s great to see continued momentum and innovation at Sintavia. The recent add
Tecnotree Posts Strong Growth in 2020 Despite Pandemic & Global Slowdown2.3.2021 13:56:00 CET | Press release
Tecnotree, the global provider of IT solutions for the telecom industry, has recently announced its Q4 and full-year 2020 financial results. In a year that will globally go down in history as the year of pandemic and resultant economic slowdown, Tecnotree posts a different story. With a substantial 76% increase in net income and 48% EBIT growth, Tecnotree displayed strong resilience even during the most difficult times. The company struck the right chord for all the key metrics in 2020; and with 4 new clients and an Order-Book of more than €32 million, Tecnotree appears set to continue the growth momentum in 2021. 2020 year performance at a glance: Net sales grew by 12% to €52.8M (€47M) Net income registered 76% growth to €13.6M (€7.7M) Earnings Before Interest and Tax (EBIT) grew by 30% to €18.6M (€14.4M) Cash & Cash Equivalent showed a 138% growth at the end of the period Share price soared by 312% in the year Market Capitalization grew by 360% to 193Me (42Me) EPS grew to 5c from 3c
Theramex Launches New Website2.3.2021 13:44:00 CET | Press release
Theramex, a global company specialised in women's health, has launched a new website. It is a modern, intuitive and easy-to-navigate site that seeks to position itself as a benchmark for information on the company's four main working areas: menopause, osteoporosis, fertility, and contraception. "This year we are strongly committed to a process of digital transformation of the company to bring it closer to our audiences: healthcare professionals, patients and users. A key step in our strategy could not be other than renewing our website and bringing it to the forefront", says Robert Stewart, CEO of the company. In the coming weeks, different new features will be implemented, and local websites will also be launched where Theramex has a presence, offering specific content adapted to the needs of each country. In addition, there will be a validated-private section for healthcare professionals where they can access information about our treatments, products and therapeutic novelties. Addin
Jetcraft Announces Partnership With Synerjet; Cementing South American Presence2.3.2021 13:00:00 CET | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is announcing a strategic relationship with Synerjet, a Latin American business aviation specialist, further strengthening the company’s footprint in the Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005544/en/ Todd Spangler, Americas Sales Director at Jetcraft (left), and Fabio Rebello, Chief Commercial Officer at Synerjet (right), mark the start of their strategic relationship. Synerjet, a Latin American business aviation specialist, will operate as an official Jetcraft authorized representative in the South America Region. (Photo: Business Wire) The aircraft sales division of Synerjet will operate as an official Jetcraft authorized representative in the South America region, enabling Jetcraft to increase its offering to its clients looking to buy, sell or trade in, with local support from Synerjet’s experienced executives. Synerjet joins J
Unifrax, Backed by Clearlake Capital, Announces Lithium Ion Battery Anode Technology Coming Early Next Year2.3.2021 13:00:00 CET | Press release
Unifrax, the leading manufacturer of high-performance specialty materials, today introduced its latest proprietary technology, SiFAB™ Silicon Fiber Anode Battery Technology by Unifrax. SiFAB, currently in advanced testing after years of research and development, has shown promising performance in multiple battery systems. This anode technology enables significantly higher energy density in lithium ion battery systems and has successfully been tested with incremental Si loadings of greater than 40 percent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005226/en/ SiFAB is Unifrax’s first step into silicon fiber for the lithium ion battery manufacturing market, building on its deep history of fiber-based technology and manufacturing. Unifrax, the inventor of specialty ceramic fibers, has a 75+ year track record of developing and supplying engineered inorganic materials at large scale to advanced industries worldwide incl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom